Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paychex, Inc. (PAYX) vs 10X Genomics Inc (TXG) Price & Performance

Paychex, Inc.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Paychex, Inc. vs 10X Genomics Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Paychex, Inc. is far larger — about 5.1× 10X Genomics Inc's market cap, and Paychex, Inc. pays a 3.91% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

PAYXTXG
Market Cap
$43.33B$8.55B
Sector
IndustrialsHealth
52-Week High
$135.46$67.29
52-Week Low
$85.57$11.34
Enterprise Value
$46.81B$8.08B
Dividend Yield
3.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paychex, Inc.

Paychex (PAYX) trades at $116.93, down 3.93% over the past day, near the consensus price target of $118.17. The stock shows strong profitability with a 27.03% net income margin and 44.77% ROE, though valuation ratios like a P/E of 24.89 and P/S of 6.73 are elevated. Recent quarters have consistently beaten EPS estimates, and the company is advancing its AI-driven WISE platform to enhance payroll efficiency. Technical indicators are mixed, with a bearish moving average signal but an oversold RSI suggesting potential near-term support.

The outlook for PAYX is cautiously optimistic, supported by steady earnings beats and strategic AI integration, but high valuation and mixed analyst sentiment pose risks. Investment opportunity lies in continued execution on margin expansion and market share gains in HR solutions, while key risks include competitive pressures and economic sensitivity affecting small business clients.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG